Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 7 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Introduction | 9 | 1 |
| Global Markets Direct Report Coverage | 9 | 1 |
| Open-Angle Glaucoma Overview | 10 | 1 |
| Therapeutics Development | 11 | 2 |
| Pipeline Products for Open-Angle Glaucoma Overview | 11 | 1 |
| Pipeline Products for Open-Angle Glaucoma Comparative Analysis | 12 | 1 |
| Open-Angle Glaucoma Therapeutics under Development by Companies | 13 | 2 |
| Open-Angle Glaucoma Therapeutics under Investigation by Universities/Institutes | 15 | 1 |
| Open-Angle Glaucoma Pipeline Products Glance | 16 | 3 |
| Late Stage Products | 16 | 1 |
| Clinical Stage Products | 17 | 1 |
| Early Stage Products | 18 | 1 |
| Open-Angle Glaucoma Products under Development by Companies | 19 | 2 |
| Open-Angle Glaucoma Products under Investigation by Universities/Institutes | 21 | 1 |
| Open-Angle Glaucoma Companies Involved in Therapeutics Development | 22 | 22 |
| Aerie Pharmaceuticals, Inc. | 22 | 1 |
| Allergan Plc | 23 | 1 |
| Amakem NV | 24 | 1 |
| Bausch &Lomb Incorporated | 25 | 1 |
| F. Hoffmann-La Roche Ltd. | 26 | 1 |
| Glaukos Corporation | 27 | 1 |
| Inotek Pharmaceuticals Corporation | 28 | 1 |
| Isarna Therapeutics GmbH | 29 | 1 |
| Kowa Company, Ltd. | 30 | 1 |
| Laboratoires Thea S.A. | 31 | 1 |
| Laboratorios Sophia S.A. de C.V. | 32 | 1 |
| Lee's Pharmaceutical Holdings Limited | 33 | 1 |
| Lexicon Pharmaceuticals, Inc. | 34 | 1 |
| Ocular Therapeutix, Inc. | 35 | 1 |
| Otsuka Holdings Co., Ltd. | 36 | 1 |
| Oxford BioMedica Plc | 37 | 1 |
| Sanofi | 38 | 1 |
| Santen Pharmaceutical Co., Ltd. | 39 | 1 |
| Senju Pharmaceutical Co., Ltd. | 40 | 1 |
| Sun Pharma Advanced Research Company Ltd. | 41 | 1 |
| Sylentis S.A.U. | 42 | 1 |
| ViSci Ltd. | 43 | 1 |
| Open-Angle Glaucoma Therapeutics Assessment | 44 | 11 |
| Assessment by Monotherapy Products | 44 | 1 |
| Assessment by Combination Products | 45 | 1 |
| Assessment by Target | 46 | 3 |
| Assessment by Mechanism of Action | 49 | 2 |
| Assessment by Route of Administration | 51 | 2 |
| Assessment by Molecule Type | 53 | 2 |
| Drug Profiles | 55 | 60 |
| (bimatoprost + brimonidine tartarate + timolol maleate) Drug Profile | 55 | 1 |
| (bimatoprost + timolol maleate) Drug Profile | 56 | 1 |
| (carteolol hydrochloride + latanoprost) Drug Profile | 57 | 1 |
| (latanoprost + netarsudil mesylate) Drug Profile | 58 | 2 |
| (latanoprost + timolol maleate) Drug Profile | 60 | 1 |
| (latanoprost + trabodenoson) Drug Profile | 61 | 1 |
| AMA-0076 Drug Profile | 62 | 2 |
| Antisense Oligonucleotides to Inhibit P16INK4a for Primary Open-Angle Glaucoma (POAG) Drug Profile | 64 | 1 |
| bamosiran Drug Profile | 65 | 3 |
| bimatoprost Drug Profile | 68 | 1 |
| bimatoprost SR Drug Profile | 69 | 2 |
| DE-117 Drug Profile | 71 | 1 |
| decorin Drug Profile | 72 | 1 |
| Glaucoma-GT Drug Profile | 73 | 1 |
| ISTH-0036 Drug Profile | 74 | 2 |
| latanoprost Drug Profile | 76 | 2 |
| latanoprost Drug Profile | 78 | 2 |
| latanoprost SR Drug Profile | 80 | 1 |
| latanoprost SR Drug Profile | 81 | 1 |
| latanoprostene bunod Drug Profile | 82 | 4 |
| levobetaxolol hydrochloride Drug Profile | 86 | 1 |
| LX-7101 Drug Profile | 87 | 1 |
| MAN-01 Drug Profile | 88 | 1 |
| MGV-354 Drug Profile | 89 | 1 |
| netarsudil mesylate Drug Profile | 90 | 5 |
| OPA-6566 Drug Profile | 95 | 1 |
| PRO-067 Drug Profile | 96 | 1 |
| R-801 Drug Profile | 97 | 2 |
| RG-4929 Drug Profile | 99 | 1 |
| ripasudil Drug Profile | 100 | 2 |
| RO-5093151 Drug Profile | 102 | 1 |
| SAR-366234 Drug Profile | 103 | 1 |
| Sepetaprost Drug Profile | 104 | 1 |
| SNJ-1656 Drug Profile | 105 | 2 |
| trabodenoson Drug Profile | 107 | 3 |
| travoprost Drug Profile | 110 | 1 |
| travoprost SR Drug Profile | 111 | 2 |
| travoprost XR Drug Profile | 113 | 2 |
| Open-Angle Glaucoma Dormant Projects | 115 | 2 |
| Open-Angle Glaucoma Discontinued Products | 117 | 1 |
| Open-Angle Glaucoma Product Development Milestones | 118 | 4 |
| Featured News &Press Releases | 118 | 1 |
| Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting | 118 | 1 |
| Apr 11, 2016: Inotek Pharmaceuticals Announces the Journal of Ocular Pharmacology and Therapeutics has Published its Phase 2 Data for Trabodenoson in Patients with Glaucoma and Ocular Hypertension | 118 | 1 |
| Mar 03, 2016: Aerie Pharmaceuticals Announces Availability on Its Website of Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting | 119 | 1 |
| Feb 22, 2016: Aerie Pharmaceuticals Announces Four New Abstracts to be Presented at the American Glaucoma Society 26th Annual Meeting Next Week | 119 | 1 |
| Mar 10, 2010: Qlt Announces Phase II Clinical Trial Results And Development Plans For The Punctal Plug Delivery System | 120 | 1 |
| Jul 28, 2009: Qlt Announces Interim Data From A Phase II Clinical Trial And A Device Study For A Punctal Plug Drug Delivery System | 121 | 1 |
| Appendix | 122 | 2 |
| Methodology | 122 | 1 |
| Coverage | 122 | 1 |
| Secondary Research | 122 | 1 |
| Primary Research | 122 | 1 |
| Expert Panel Validation | 122 | 1 |
| Contact Us | 122 | 1 |
| Disclaimer | 123 | 1 |